Recovery in mild COVID patients,Randomised Controlled Trials Budesonide vs Usual Care :

RECOVERY in mild COVID patients,Randomised Controlled Trials Budesonide vs Usual Care :
– Time to recovery was 1 day shorter in the STOIC trial and 2.94 days shorter in the PRINCIPLE trial in the budesonide group compared to usual care. (1, 2)
– both trials indicated a quicker resolution/reduction of symptoms in the budesonide group. (1,2)
– both trials were open-label (participants know if they are taking ICS or not) implying a potentially significant placebo effect, particularly for self-reported time to recovery.

Categories: COVID

Author: Agnes

Entry Date: 21/09/2021

Source 1 Name: Ramakrishnan S, Nicolau DV, Jr., Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine. 2021;9(7):763-72.

Source 1 URL:

Source 2 Name: Yu L-M, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. The Lancet. 2021;398(10303):843-55.

Source 2 URL:

Source 3 Name:

Source 3 URL:

Source 4 Name:

Source 4 URL:

Source 5 Name:

Source 5 URL:

Source 6 Name:

Source 6 URL: